primarily revolving around promising clinical trial results for Silence Therapeutics’ lead product candidate, zerlasiran. The recent data from the ALPACAR-360 phase II study presented at the American ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback